Find Federal Grants
Investigation of Monkeypox and Other Zoonotic Diseases in the Democratic Republic of the Congo (DRC)
Centers for Disease Control and Prevention - ERA · RFA-CK-22-001
Catalyze: Product Definition Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)
National Institutes of Health · RFA-HL-23-013
Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)
National Institutes of Health · RFA-HL-23-012
Catalyze: Product Definition Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)
National Institutes of Health · RFA-HL-23-014
National Institutes of Health · RFA-MH-22-155
Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
National Institutes of Health · RFA-HL-23-011
Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
National Institutes of Health · RFA-HL-23-010
ARDS, Pneumonia, and Sepsis Phenotyping Consortium Coordinating Center (U01 Clinical Trial Not Allowed)
National Institutes of Health · RFA-HL-23-002
ARDS, Pneumonia, and Sepsis Phenotyping Consortium Clinical Centers (U01 Clinical Trial Not Allowed)
National Institutes of Health · RFA-HL-23-001
Advancing Research on Mechanisms and Management of Pain for Diseases and Conditions within NIDDK Mission Areas (R01 Clinical Trial Optional)
National Institutes of Health · RFA-DK-22-005
Emergency Award HEAL Initiative: Developing and Optimizing Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional)
National Institutes of Health · RFA-MH-22-176
Emergency Award HEAL Initiative: Optimizing Existing Evidence-Based Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional)
National Institutes of Health · RFA-MH-22-175
BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative (R01 Clinical Trial Not Allowed)
National Institutes of Health · RFA-MH-22-145
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)
National Institutes of Health · PAR-22-099
HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans (R21 Clinical Trials Not Allowed)
National Institutes of Health · RFA-DE-22-011
Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)
National Institutes of Health · PAR-22-058
Revolutionizing Innovative, Visionary Environmental Health Research (RIVER) (R35 Clinical Trial Optional)
National Institutes of Health · RFA-ES-22-002
Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)
National Institutes of Health · PAR-22-083
Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (UT1/UT2 Clinical Trial Optional)
National Institutes of Health · PAR-22-103
Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)
National Institutes of Health · PAR-22-084